Abstract
Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Current Pharmaceutical Design
Title: Molecular Pharmacology of Non-L-type Calcium Channels
Volume: 11 Issue: 15
Author(s): Clinton J. Doering and Gerald W. Zamponi
Affiliation:
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Abstract: Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Export Options
About this article
Cite this article as:
Doering J. Clinton and Zamponi W. Gerald, Molecular Pharmacology of Non-L-type Calcium Channels, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021042
DOI https://dx.doi.org/10.2174/1381612054021042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Pharmacotherapies for Alcoholism: The Old and the New (Guest Editor: M. Foster Olive)]
CNS & Neurological Disorders - Drug Targets Bioactivity Guided Isolation of Quercetin as Anxiolytic Compound from Elaeocarpus ganitrus Beads
The Natural Products Journal Application of NMR Screening in Drug Discovery
Current Topics in Medicinal Chemistry Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Study of Some Piperine Analogues on Drugs Efflux by Targeting P-glycoprotein, an in silico Approach
Letters in Drug Design & Discovery Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology The Metabolism of Methazolamide - Identification of Metabolites in Guinea Pig Urine
Drug Metabolism Letters Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy
Current Drug Targets Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments
Current Pharmaceutical Design